Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Genentech's BRAF inhibitor Zelboraf (vemurafenib) for Erdheim-Chester disease based on data from a basket trial involving 22 patients, the first time a drug has been approved based solely on such a trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.